Innovent receives NMPA approval for Tabosun colon cancer treatment
Approval was based on the pivotal Phase III NeoShot trial.
Drug Development
Gilead Sciences to acquire Repare’s RP-3467
Zydus and Bioeq partner for commercialisation of Nufymco in US
Genentech secures FDA approval for Lunsumio VELO SC for follicular lymphoma
Samsung Biologics to acquire Human Genome Sciences
Cytokinetics receives FDA approval for MYQORZO tablets for oHCM
J&J receives FDA approval for lung cancer therapy
EC approves Incyte’s Minjuvi combo for follicular lymphoma
